Fortress Biotech (FBIOP) Stock Price, News & Analysis

Date:

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of…

Read more…

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Tampa RV giant Lazydays to delist from Nasdaq

Tampa-based Lazydays Holdings Inc., one of Florida’s most recognized...

Granite Geek: New Hampshire might get access to ‘balcony solar’

I had solar panels put on my roof six...

TSX Today: What to Watch for in Stocks on Monday, November 10

Despite firm gold and silver prices, Canadian stocks...

While BNB and DOT Struggle Under Market Pressure, BlockDAG’s Presale Soars Past $435M!

As market-wide fear grips the sector, the Binance Coin...